{"preliminary_commentary":{"by_channel":{"podcast":15,"youtube":10,"x_thread":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04686305\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"DL03","nct_id":"NCT04686305","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dl03-nct04686305. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DL03","arms":[{"description":"T-DXd, Durvalumab and Cisplatin","label":"Arm 1A: T-DXd, Durvalumab and Cisplatin","type":"EXPERIMENTAL"},{"description":"T-DXd, Durvalumab and Carboplatin","label":"Arm 1B: T-DXd, Durvalumab and Carboplatin","type":"EXPERIMENTAL"},{"description":"T-DXd, Durvalumab and Pemetrexed (Arm not initiated)","label":"Arm 1C: T-DXd, Durvalumab and Pemetrexed","type":"EXPERIMENTAL"},{"description":"T-DXd","label":"Arm 1D: T-DXd","type":"EXPERIMENTAL"},{"description":"Drug: T-DXd and Volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig","label":"Arm 3A: T-DXd and Volrustomig","type":"EXPERIMENTAL"},{"description":"Drug: T-DXd, Volrustomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion Other Name: Volrustomig Drug: Carboplatin Carboplatin: administered as an IV infusion","label":"Arm 3B: T-DXd, Volrustomig and Carboplatin","type":"EXPERIMENTAL"},{"description":"T-DXd and Rilvegostomig Drug: T-DXd, Rilvegostomig T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936","label":"Arm 4A: T-DXd and Rilvegostomig","type":"EXPERIMENTAL"},{"description":"Drug: T-DXd, Rilvegostomig and Carboplatin T-DXd: administered as an IV infusion Other Name: DS-8201a, Trastuzumab deruxtecan Biological/Vaccine: Rilvegostomig Rilvegostomig: administered as an IV infusion Other Name: Rilvegostomig, AZD2936 Drug: Carboplatin Carboplatin: administered as an IV infusion","label":"Arm 4B T-DXd and Rilvegostomig with Carboplatin","type":"EXPERIMENTAL"},{"description":"Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (priming dose in first cycle, fixed dose in subsequent cycles) Other Name: volrustomig","label":"Arm 5A: T-DXd and Volrustomig","type":"EXPERIMENTAL"},{"description":"Drug: T-DXd and volrustomig T-DXd: administered as an IV infusion Other Name: DS-8201a, trastuzumab deruxtecan Biological/Vaccine: Volrustomig Volrustomig: administered as an IV infusion (fixed dose from first cycle onward) Other Name: volrustomig","label":"Arm 5B: T-DXd and Volrustomig","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":304,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"T-DXd","otherNames":["DS-8201a, Trastuzumab deruxtecan"],"type":"DRUG"},{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"BIOLOGICAL"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Volrustomig","otherNames":["Other Name: MEDI5752"],"type":"DRUG"},{"name":"Rilvegostomig","otherNames":["Other Name: AZD2936"],"type":"DRUG"}],"last_update":"2026-04-13","lead_sponsor":"AstraZeneca","official_title":"A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Frequency of AEs and SAEs","timeFrame":"Safety and tolerability (and to determine RP2D) will be assessed for approximately 20 months from informed consent"}],"references":[{"citation":"Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY, Samol J, Runglodvatana Y, Lee KY, Chang GC, Lee CH, Kowalski D, Saw SPL, Huang Y, Ruiter G, Ahn MJ, Yang TY, Yang CT, Sookprasert A, Nakajima EC, Alfon J, McEwen R, Chang YT, Yang JC. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. J Thorac Oncol. 2026 May;21(5):103541. doi: 10.1016/j.jtho.2025.12.080. Epub 2025 Dec 23.","pmid":"41448488","type":"DERIVED"}],"start_date":{"date":"2021-03-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","url":"https://clinicaltrials.gov/study/NCT04686305"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dl03-nct04686305"}